Global Granulocyte-Colony Stimulating Factor (G-CSF) Market Growth 2026-2032

The global Granulocyte-Colony Stimulating Factor (G-CSF) market size is predicted to grow from US$ million in 2025 to US$ million in 2032; it is expected to grow at a CAGR of %from 2026 to 2032.

Granulocyte-Colony Stimulating Factor (G-CSF) is a hematopoietic growth factor that stimulates the production and release of neutrophils, a type of white blood cell critical for fighting infections. G-CSF exists in both short-acting and long-acting forms, each designed to maintain neutrophil counts in patients with conditions like chemotherapy-induced neutropenia. Short-acting G-CSF, such as filgrastim, requires daily administration due to its rapid clearance from the body. In contrast, long-acting G-CSF, like pegfilgrastim, is modified with polyethylene glycol (PEG) to extend its half-life, allowing for less frequent dosing, typically once per chemotherapy cycle.

United States market for Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Granulocyte-Colony Stimulating Factor (G-CSF) is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Granulocyte-Colony Stimulating Factor (G-CSF) players cover Amgen, Pfizer, Chugai Pharmaceutical, Tanvex BioPharma, Kashiv BioSciences, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the “Granulocyte-Colony Stimulating Factor (G-CSF) Industry Forecast” looks at past sales and reviews total world Granulocyte-Colony Stimulating Factor (G-CSF) sales in 2025, providing a comprehensive analysis by region and market sector of projected Granulocyte-Colony Stimulating Factor (G-CSF) sales for 2026 through 2032. With Granulocyte-Colony Stimulating Factor (G-CSF) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Granulocyte-Colony Stimulating Factor (G-CSF) industry.

This Insight Report provides a comprehensive analysis of the global Granulocyte-Colony Stimulating Factor (G-CSF) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Granulocyte-Colony Stimulating Factor (G-CSF) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Granulocyte-Colony Stimulating Factor (G-CSF) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Granulocyte-Colony Stimulating Factor (G-CSF) and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Granulocyte-Colony Stimulating Factor (G-CSF).

This report presents a comprehensive overview, market shares, and growth opportunities of Granulocyte-Colony Stimulating Factor (G-CSF) market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Long-acting G-CSF
Short-acting G-CSF

Segmentation by Application:
Neutropenia
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Amgen
Pfizer
Chugai Pharmaceutical
Tanvex BioPharma
Kashiv BioSciences
Sandoz
Teva
Mylan
Coherus BioSciences
Italfarmaco SpA
Evive Biotech
Jiangsu Hengrui Pharmaceuticals
Amoytop Biotech
Qilu Pharmaceutical
CSPC Baike Biopharma
SL Pharm
Lunan Pharmaceutical
Shanghai Sunway Biotech
Changchun GeneScience Pharmaceutical
Harbin Pharmaceutical Group
Hangzhou Jiuyuan Gene Engineering
Kexing Biopharm
North China Pharmaceutical

Key Questions Addressed in this Report

What is the 10-year outlook for the global Granulocyte-Colony Stimulating Factor (G-CSF) market?

What factors are driving Granulocyte-Colony Stimulating Factor (G-CSF) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Granulocyte-Colony Stimulating Factor (G-CSF) market opportunities vary by end market size?

How does Granulocyte-Colony Stimulating Factor (G-CSF) break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver. Show more